UK edition London open
Markets
Delayed · 08:17 UK
Wednesday 28 October 2026 · London open
Topic
Every Financial News story tagged pharmaceuticals, newest first.
11–20 of 23
Mace has announced significant promotions within its contracting division.Rob Lemming is appointed Managing Director of Public Sector & Life Sciences.Alister Grey assumes the role of Managing Director for Technology &…
Biotech giant Shire has said it would be willing to recommend an amended $64bn takeover bid from Takeda Pharmaceutical Co to shareholders, according to Reuters. The rare disease specialist made…
Irish biotechnology firm Elan Corp plc (NYSE:ELN) said it was launching a formal sale given expressions of interest it had received and would invite hostile suitor RP Management LLC (Royalty…
Swiss pharma major Novartis AG (VTX:NOVN) does not intend to pursue a takeover of US drugmaker Actavis Inc (NYSE:ACT), a company spokesperson told Reuters, refuting a previous report by the…
UK drug maker GlaxoSmithKline Plc (LON:GSK) said today it had increased its stake in its Indian unit GlaxoSmithKline Consumer Healthcare Ltd to 72.5% from 43.2%, as part of a voluntary…
British drugmaker GlaxoSmithKline Plc (LON:GSK) is seen to increase to some USD14.00 (EUR11.43) a share, or around USD2.8bn in total, from USD13.00 per share, its bid to buy US biopharmaceutical…
US diagnostic testing specialist Genova Diagnostics Inc said it had acquired clinical laboratory tests provider Metametrix Inc for an undisclosed sum. Following the transaction, Metametrix's chief executive officer Dr Alexander…
US biopharmaceutical firm Human Genome Sciences (NASDAQ:HGSI), or HGS, reiterated its advice to shareholders not to tender their stock to the $13.00 (EUR10.30) a share hostile takeover offer from GlaxoSmithKline…
US pharmaceutical group Bristol-Myers Squibb Co (NYSE:BMY) said it had made an agreement to buy diabetes-focused biopharmaceutical firm Amylin Pharmaceuticals Inc (NASDAQ:AMLN) at U$31.00 (€24.50) in cash per share, or…
US biopharmaceutical firm Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) has once again prolonged its tender bid to take over anti-cancer therapeutics specialist Allos Therapeutics Inc (NASDAQ:ALTH), this time until 22 June 2012,…
Page 2 of 3
